Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Mirdametinib
Cat. No.:
OB0225LY-0472
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Mirdametinib is an inhibitor of MEK with antitumor activity that targets cell signaling pathways in multiple tumor types.
Synonym:
PD325901; PD0325901; 391210-10-9; (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide; N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
CAS No.:
391210-10-9
Compound CID:
9826528
Formula:
C16H14F3IN2O4
Formula Weight:
482.19
Specification
Relative Density:
1.818 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Mirdametinib can be used in tumor biology research or play an important role in signal transduction pathway research.
Library Information
Targets:
MEK
Pathways:
MAPK; Apoptosis; Autophagy
Plate Number:
AOCL-7
Plate Location:
a10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 103.69 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.37 mM), insoluble in water.
